This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
2025's Top 3 Breakout Stocks for Active Traders: Don't Miss Out!
by Tirthankar Chakraborty
ORLA, FIGS and CMPX emerge as breakout candidates as traders scan for stocks nearing or clearing key resistance levels.
ORLANegative Net Change FIGSNegative Net Change CMPXNegative Net Change
biotechnology medical retail
Four PEG-Driven GARP Winners for the Uncertainty of November 2025
by Urmimala Biswas
Four PEG-driven GARP picks emerge as compelling options amid market turmoil, with ALL, SANM, PAHC and ENS highlighted for their strong growth metrics.
ALLPositive Net Change SANMNegative Net Change ENSNegative Net Change PAHCNegative Net Change
finance industrial-products insurance medical medical-devices tech-stocks
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
by Ekta Bagri
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
BMYPositive Net Change JNJPositive Net Change PFENegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
by Zacks Equity Research
Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
ALKSNegative Net Change AGIOPositive Net Change CRMDNegative Net Change FULCNegative Net Change
biotechs medical
TDOC vs. LFMD: Which Telehealth Stock Is Better for Your Portfolio?
by Tanuka De
TDOC and LFMD face contrasting paths as telehealth demand climbs, with fundamentals and growth plans shaping which stock stands out.
TDOCNegative Net Change LFMDNegative Net Change
medical
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
by Zacks Equity Research
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
ADMAPositive Net Change EDITNegative Net Change COGTNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
by Zacks Equity Research
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Stocks like PAHC, ATRO, COMM and HRTG are seeing price strength and have a high chance of carrying the momentum forward.
ATRONegative Net Change COMMNegative Net Change PAHCNegative Net Change HRTGNegative Net Change
aerospace artificial-intelligence finance medical tech-stocks
Best Momentum Stock to Buy for Nov. 20th
by Zacks Equity Research
PAHC, SHIP and BCAL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 20, 2025.
PAHCNegative Net Change SHIPNegative Net Change BCALPositive Net Change
finance medical transportation
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
by Zacks Equity Research
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
MRKNegative Net Change GILDNegative Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
CVS Aetna's New Generative AI Assistant Aims to Simplify Health Care
by Moumi Mondal
CVS Health's Aetna debuts an embedded generative AI assistant designed to simplify benefits navigation and elevate the consumer health experience.
CAHPositive Net Change CVSNegative Net Change CNCNegative Net Change
medical medical-devices
RVP Stock Rises Post Q3 Earnings Despite Tariff and Cost Pressures
by Zacks Equity Research
Retractable Technologies reports improved third-quarter 2025 earnings driven by better margins, investment gains and a shift toward domestic production.
RVPNegative Net Change
earnings medical medical-devices
Reasons to Add HealthEquity Stock to Your Portfolio for Now
by Zacks Equity Research
HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q2 results, though data security threats remain a key risk.
BSXNegative Net Change ISRGNegative Net Change HQYNegative Net Change MEDPNegative Net Change
medical medical-devices
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
by Zacks Equity Research
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal
by Zacks Equity Research
DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 diabetes patients by integrating with the G7 15 day sensor.
MASIPositive Net Change DXCMNegative Net Change GMEDNegative Net Change MEDPNegative Net Change
medical medical-devices
Best Income Stocks to Buy for Nov. 20th
by Zacks Equity Research
SHIP, PAHC and FCFS made it to the Zacks Rank #1 (Strong Buy) income stocks list on November 20, 2025.
FCFSNegative Net Change PAHCNegative Net Change SHIPNegative Net Change
business-services medical transportation
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?
by Zacks Equity Research
Embecta's Q4 earnings loom as product momentum, global trends and recent strategic gains set the stage for potential top-line support.
MEDPNegative Net Change ALZNNegative Net Change EMBCNegative Net Change BTSGPositive Net Change
earnings medical
TMO Stock May Rise Post New PCR Test in Collab With Coca-Cola Partner
by Zacks Equity Research
Thermo Fisher's new all-in-one SureTect qPCR assay promises faster, broader beverage spoilage detection and sharper quality control.
BSXNegative Net Change TMONegative Net Change MEDPNegative Net Change
medical
ICCC Stock Down Despite Y/Y Q3 Earnings Improvement & Margin Strength
by Zacks Equity Research
ImmuCell tumbles despite stronger margins and a rebound in EPS, as backlog dynamics pressure quarterly sales while management highlights improving operations.
ICCCNegative Net Change
earnings medical
3 Stocks With Upgraded Broker Ratings to Buy for Solid Returns
by Swayta Shah
Upgraded broker ratings bring the spotlight to PODD, SNDK and OI as potential picks in a selective market, each showing strong earnings growth and momentum.
OIPositive Net Change SNDKNegative Net Change PODDNegative Net Change
computers industrial-products medical medical-devices tech-stocks
New Strong Buy Stocks for Nov. 20: CMC, BCAL, and More
by Zacks Equity Research
CMC, BCAL, FCFS, PAHC and SHIP have been added to the Zacks Rank #1 (Strong Buy) List on November 20, 2025.
FCFSNegative Net Change CMCNegative Net Change PAHCNegative Net Change SHIPNegative Net Change BCALPositive Net Change
business-services finance industrial-products medical transportation
Zacks.com featured highlights include Tactile Systems, Canadian Natural Resources, Arlo and Celestica
by Zacks Equity Research
Tactile Systems, Canadian Natural Resources, Arlo and Celestica stand out for strong efficiency metrics and consistent earnings surprises.
CLSNegative Net Change CNQNegative Net Change TCMDNegative Net Change ARLONegative Net Change
medical
TDOC Partners With TytoCare to Expand At-Home Exam Capabilities
by Zacks Equity Research
Teladoc Health deepens its virtual care reach by adding TytoCare's at-home exam tech to Primary360 and 24/7 Care starting in 2026.
UHSNegative Net Change TDOCNegative Net Change VCYTPositive Net Change BTSGPositive Net Change
medical
ELTP Stock Declines Despite Solid Q2 Earnings and Revenue Performance
by Zacks Equity Research
Elite Pharmaceuticals delivers record second-quarter fiscal 2026 earnings as lisdexamfetamine sales surged, though margins faced competitive pressure.
ELTPNegative Net Change
earnings medical
Vaso Stock Up Following Strong Q3 Earnings and Profit Turnaround
by Zacks Equity Research
VASO reports a third-quarter 2025 profit turnaround with higher revenue, stronger margins and robust cash flow from subscriptions.
VASONegative Net Change
earnings medical medical-devices